Skip to main content
Premium Trial:

Request an Annual Quote

NCI Seeking Licensee for Colorectal Cancer Biomarkers, Methods of Detection


This story originally ran on Dec. 10.

The National Cancer Institute this week made available for licensing protein biomarkers and methods for the detection of colorectal cancer.

The biomarkers and methods were identified and developed by NCI researchers Thomas Ried and Jens Habermann, the institute said in an announcement. Using the SELDI-TOF platform, now marketed and sold by Bio-Rad Laboratories, they identified 13 biomarkers and showed “that SELDI-TOF based serum marker protein profiling enables minimally invasive detection of colon cancer with 96.7 percent sensitivity and 100 percent specificity,” NCI said.

A patent application, number 20090142332, covering the invention was filed on Sept. 21, 2007, with the US Patent and Trademark Office.

In the application, Ried and Habermann said that their invention provides for the first time novel protein markers that are differentially expressed in patients with colon cancer, compared to healthy patients. The invention also provides kits, and “sensitive and quick” methods for determining a patient’s colon cancer status using the biomarkers.

According to the NCI, colorectal cancer is the third most common cancer and the third leading cause of cancer mortality in the US. In 2009, 106,100 new cases of colon cancer and 40,780 new cases of rectal cancer in the US are projected. Combined, the two cancers are projected to kill 49,920 Americans in 2009.

Current methods of diagnosing the disease include sigmoidoscopy, colonoscopy, and fecal occult blood tests. However, such methods are uncomfortable, resulting in a large non-compliance rate or high rate of false-positive results.

“The claimed invention has the potential to be a widely used, easy-to-use, and inexpensive diagnostic,” the NCI said. Those interested in licensing the invention should contact Surekha Vathyam at [email protected] or (301) 435-4076.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.